

# EUnetHTA

**Marcus Guardian, Chief Operations Officer EUnetHTA,**


# EUnetHTA JA3 Participants

**81 partners of 29 countries,**  
consisting of national, regional  
and non-for-profit agencies that  
produce or contribute to HTA

**Project Coordinator:**  
The Dutch National Health  
Care Institute (ZIN)



# HTA input along drug life cycle



# EUnetHTA HTA Core Model®

## SCOPE

Comprehensive/ Full HTA


Clinical domains

Non-clinical domains


## HTA Core Model DOMAINS

1. Health problem and current use of technology
2. Description and technical characteristics
3. Safety
4. Clinical effectiveness
5. Costs and economic evaluation
6. Ethical analysis
7. Organisational aspects
8. Patient and social aspects
9. Legal aspects

# Joint HTA production







# EUnetHTA Stakeholders



## Alignment in ISCs between HTABs

<b>Full agreement</b>	HTABs provide a common response Does not prevent supplementary national specifications
<b>Partial agreement</b>	> 50% of HTA bodies agree on a common response
<b>Disagreement</b>	< 50% of HTA bodies agree on a common response



No disagreement


P = O:  
full 85.7%  
partial 14.3%

C:  
full 78.6%  
partial 21.4%

# Thank you!




# Timelines Joint Assessment (Pharma)




# EU Regulatory Process

# WP4 HTA Process

# Stakeholder involvement



# WP4 pharma - Scoping Phase



# WP4 pharma - Assessment Phase

